A flexible, pan-species, multi-antigen platform for the detection and monitoring of SARS-CoV-2-specific antibody responses.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
27 Jan 2021
27 Jan 2021
Historique:
pubmed:
4
2
2021
medline:
4
2
2021
entrez:
3
2
2021
Statut:
epublish
Résumé
The SARS-CoV-2 pandemic and the vaccination effort that is ongoing has created an unmet need for accessible, affordable, flexible and precise platforms for monitoring the induction, specificity and maintenance of virus-specific immune responses. Herein we validate a multiplex (Luminex-based) assay capable of detecting SARS-CoV-2-specific antibodies irrespective of host species, antibody isotype, and specimen type (e.g. plasma, serum, saliva or blood spots). The well-established precision of Luminex-based assays provides the ability to follow changes in antibody levels over time to many antigens, including multiple permutations of the most common SARS-CoV-2 antigens. This platform can easily measure antibodies known to correlate with neutralization activity as well as multiple non-SARS-CoV-2 antigens such as vaccines (
Identifiants
pubmed: 33532799
doi: 10.1101/2021.01.20.21249279
pmc: PMC7852250
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI125738
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NCEZID CDC HHS
ID : U54 CK000485
Pays : United States
Organisme : NIGMS NIH HHS
ID : P41 GM103390
Pays : United States
Organisme : ACL HHS
ID : U54CK000485
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400004C
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no conflicts of interest exists.